Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• MET receptor tyrosine kinase (RTK) inhibitors have shown limited success in cancer treatment due to challenges in patient selection.
• Epidermal growth factor receptor (EGFR) inhibitors are effective against lung tumors with specific EGFR kinase domain mutations.
• MET exon 14 skipping mutations represent a distinct mechanism of RTK activation.

Purpose of the Study:

• To review the molecular mechanisms underlying MET exon 14 skipping and subsequent MET receptor activation.
• To compare MET exon 14 skipping-induced activation with classical RTK kinase domain mutations.
• To discuss the clinical characteristics and therapeutic sensitivity of MET exon 14 skipping mutations in cancer patients.

Main Methods:

• Review of recent publications and case reports on MET exon 14 skipping mutations.
• Analysis of molecular mechanisms of MET receptor regulation and activation.
• Clinical data review of patients with MET exon 14 skipping mutations treated with MET inhibitors.

Main Results:

• Mutations causing MET exon 14 skipping lead to aberrant MET receptor activation.
• Case reports demonstrate objective responses to MET-targeting tyrosine kinase inhibitors in patients with these mutations.
• This suggests a potential therapeutic strategy, especially for lung cancer.

Conclusions:

• MET exon 14 skipping mutations represent a targetable driver alteration in cancer, particularly lung cancer.
• MET inhibitors show clinical activity in patients with MET exon 14 skipping mutations.
• Future challenges include patient screening and managing resistance to MET inhibitors.